Professor Mark Schembri is a prominent microbiologist with experience in combating the global health crisis presented by multi-drug resistant pathogens. Professor Schembri's expertise on the virulence of bacterial pathogens and his innovative analysis of biofilm formation aims to improve the outcomes of the >400 million individuals that suffer from urinary tract infections each year across the globe.

Through the application of genetic, genomic and functional studies on uropathogenic E. coli, Professor Schembri has identified targets to reduce the virulence of this pathogen, and will pursue the development of life-saving therapeutic and preventative advances with the assistance of NHMRC, MRFF and ARC grants. Professor Schembri has tracked the rapid emergence and global spread of a virulent, drug-resistant E. coli clone and used genome sequencing to understand its evolution and virulence.

Links: Professor Schembri collaborates with national and international research leaders, including in Denmark, where he was a lecturer. Professor Schembri has strong links with other international experts in his field, including at the Pasteur Institute and the Wellcome Trust Sanger Institute in Cambridge. His research collaborations also span lead groups at UQ and other top Australian institutes, including Griffith and La Trobe Universities.

Membership, Funding and patents: Since 2014, Professor Schembri has been awarded over $15 million in funding from competitive national research funding bodies. He holds provisional patents for the development of novel therapeutic agents and vaccine antigens. He is a Fellow of the American Academy of Microbiology, and is regularly invited to speak at international conferences in his field.

Awards and Communication: Professor Schembri was the recipient of the Frank Fenner Award (2010) and the ASM BacPath Oration Award (2019) for his outstanding original research contribution to the study of Infectious Disease. He was an Australian Research Council Future Fellow (2011-2015) a National Health and Medical Research Council Senior Research Fellow (2016-2020). Professor Schembri is the author of >240 peer-reviewed research manuscripts. He is President of the Australian Society for Microbiology (2022-2026).

Professor Jennifer Stow is a molecular cell biologist, an NHMRC Leadership Fellow and head of the Protein Trafficking and Inflammation research laboratory in The University of Queensland's Institute of Molecular Bioscience (IMB). Her previous leadership appointments include as Division Head and Deputy Director (Research) at IMB (12 years) and she currently serves on national and international advisory boards, editorial boards and steering committees, and as an elected Associate Member of the European Molecular Biology Organisation (EMBO).

Jenny Stow received her undergraduate and PhD qualifications at Melbourne's Monash University before undertaking postdoctoral training in the Department of Cell Biology at Yale University School of Medicine, USA. With training as a microscopist in kidney research, she gained further experience at Yale as a postdoc in the lab of eminent cell biologist and microscopist, Dr Marilyn Farquhar, where protein trafficking was both a theme and a passion. Jenny then took up her first faculty appointment as an Assistant Professor in the Renal Unit at Massachusetts General Hospital (MGH) and Harvard Medical School in Boston USA, where her research uncovered new roles for a class of enzymes, GTPases, in regulating trafficking within cells. At MGH her research also formed part of a highly successful NIH Renal Cell Biology Program. In late 1994, Jenny moved her research lab back to Australia, to The University of Queensland, in late 1994 as a Wellcome Trust International Medical Research Fellow. As part of IMB since, the Stow lab has continued a focus on protein trafficking, including pioneering live-cell imaging, to spearhead their work on trafficking in inflammation, cancer and chronic disease. Major discoveries include identifying new proteins and pathways for recycling adhesion proteins in epithelial cells, inflammatory cytokine secretion in macrophages and immune signalling through Toll-like receptors in inflammation and infection. Small GTPases of the Rab family, signalling adaptors and kinases feature among the molecules studied in the Stow lab for their functional roles and their potential as drug targets in inflammation and cancer. A keen focus is to understand the role of the fluid uptake pathway, macropinocytosis, in controlling inflammation, cancer and mucosal absorption.

Professor Stow has been awarded multiple career fellowships including from American Heart Association, Wellcome Trust and NHMRC. She has published >200 papers, cited over 15,500 times and she is the recipient of awards and honours, most recently including the 2019 President's Medal from the Australia and New Zealand Society for Cell and Developmental Biology. She is also academic head of IMB Microscopy, a world-class fluorescence microscopy and image analysis facility. Her research is funded by a variety of agencies and industry partnerships, in addition to NHMRC and ARC, including through the ARC Centre of Excellence in Quantum Biotechnology, QUBIC. The Stow lab work with national and international collaborators and welcome students and postdoctoral trainees to participate in their research. We value having a diverse, inclusive and supportive culture for research and celebrate the many diverse and wonderful successes of Stow lab alumni.